Navigation Links
Quest Diagnostics to Provide Nationwide Access to Natera's New Non-Invasive Prenatal Test

MADISON, N.J. and SAN CARLOS, Calif., Feb. 20, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.

Panorama uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome). Panorama can be used as early as the ninth week of pregnancy.

Physician clients of Quest Diagnostics will be able to forward specimens for testing to Natera's CLIA-certified laboratory in San Carlos, Calif., which developed and validated the lab-developed Panorama test. The test will be made available to physician clients of Quest Diagnostics in certain regions in March and nationwide in the United States in April 2013. Additional terms were not disclosed.

"Cell-free fetal DNA testing is a significant advance in prenatal screening," said Charles Strom , M.D., Ph.D., senior medical director, genetics, Quest Diagnostics Nichols Institute. "By offering physicians and women access to Panorama, Quest Diagnostics is delivering on its commitment to provide clinically important innovations aligned with guideline-based care."

Panorama is a non-invasive screening test that provides early information for assessing pregnancy risks. A 'low risk' Panorama test result indicates a lower likelihood that a pregnancy is affected. With this information, a woman may consider, in consultation with her physician and results of other medical assessments, whether to pursue or forgo invasive diagnostic testing, which carries a slight risk of miscarriage. A 'low risk' Panorama result does not guarantee an unaffected pregnancy.

In December 2012, the American Congress of Obstetricians and Gynecologists (ACOG) issued a medical opinion stating that cell-free fetal DNA testing is one option that can be used as a primary screening test in women at increased risk of aneuploidy. It may also be offered as a follow-up test for women with a positive first-trimester or second-trimester screening test result. Risk factors include advanced maternal age (35 years or older), a maternal serum screen indicating high risk, ultrasound abnormality and/or a history of prior pregnancy with a trisomy. ACOG also recommends physicians counsel patients on the limitations of these tests, including inability to confirm a pregnancy is not affected.

"Our Panorama test uses advanced SNP-based technology to provide physicians and expecting mothers with safe, reliable screening information, early in the pregnancy," said Matthew Rabinowitz , Ph.D., chief executive officer of Natera. "The broad availability of the test through Quest Diagnostics, a leader in women's health diagnostics, will help many more women and parents access DNA-based non-invasive prenatal screening."

Quest Diagnostics Women's Health Services

Quest Diagnostics is provider of comprehensive diagnostic information services for women's health disorders across the continuum of a woman's life. The company's specialized services feature one of the broadest menus of genetic services for pregnancy, including carrier screening for spinal muscular atrophy, cystic fibrosis and fragile X syndrome. The company also provides diagnostic information services for cervical, breast and ovarian cancer, and sexually transmitted diseases and reproductive tract infections. In addition, Quest Diagnostics provides genetic counseling services for clinicians and parents and publishes original research on women's health issues in peer-reviewed journals and at scientific conferences.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at Follow us at and

About Natera

Natera is a leading genetic testing company that has developed a proprietary bioinformatics-based technology (NATUS) to deliver accurate and comprehensive high-throughput testing for reproductive indications from tiny quantities of DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening tests to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as 9 weeks. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit

Quest Diagnostics Contacts:
Wendy Bost (Media): 973-520-2800
Dan Haemmerle (Investors): 973-520-2900

Natera Contacts:
Russo Partners
Ian Stone , 619-308-6541
Natera, Inc.
Gautam Kollu , 650-249-9090


SOURCE Quest Diagnostics Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
2. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
3. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
4. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
5. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
6. Questcor to Report Second Quarter Results on July 24, 2012
7. Watson and Actavis Receive FTC Second Request
8. Questcor Reports Second Quarter Financial Results
9. Roper Industries to Acquire Sunquest Information Systems
10. Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
11. Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Healths TERC Gene Marker
Post Your Comments:
(Date:10/12/2015)... , Oct. 12, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental ... for the third quarter of 2015, its guidance for ... has secured a $50 million Senior Secured Credit Facility. ...
(Date:10/12/2015)... Okla. , Oct. 12, 2015  Millions of ... free from the shackles of tobacco. An April ... at Kings College London showed electronic cigarettes to be ... smoking. But more than a decade after the technology ... it remained unchanged.    --> ...
(Date:10/12/2015)... NEW YORK , Oct. 12, 2015 /PRNewswire/ ... devices used to improve and enhance the quality ... injectors comprise chemical substances (contrast media) used in ... imaging, and angiography. These devices allow the radiologists ... normal and abnormal conditions of the body. Contrast ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, Inc., the ... of Synergy 2015. The annual WennSoft KEY2ACT user conference will take place from ... unite customers, partners, WennSoft team members and sponsors to facilitate the sharing of ...
(Date:10/13/2015)... ... , ... Scientists in Seattle and Vancouver compared the diagnostic value of lung ... Surviving Mesothelioma has just posted an article on the new research. Click here ... the University of British Columbia found that certain genetic alterations were seen just as ...
(Date:10/13/2015)... ... October 13, 2015 , ... Georgia Partnership for ... communities throughout Georgia, along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and ... summits for Fall 2015. , Each of the three conferences share this ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... university’s new School of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice ... and education that has spanned four decades. , Dr. McLeod’s long and successful ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, ... Conference on August 26. Berry, who owns and operates Gold's Gym Cheyenne ... growing Gold’s Gyms in the United States. A brand leader in global fitness, Gold’s ...
Breaking Medicine News(10 mins):